Rational design of multitargeted tyrosine kinase inhibitors: a novel approach

Area of Science:

• Molecular Biology
• Oncology
• Medicinal Chemistry

Background:

• Non-receptor Src tyrosine kinase collaborates with epidermal growth factor receptor (EGFR) in solid tumor invasion and metastasis.
• Targeting both EGFR and Src is a promising strategy for developing novel anti-cancer agents.

Purpose of the Study:

• To design and synthesize novel chimeric molecules (combi-molecules) capable of simultaneously inhibiting both EGFR and Src kinases.
• To identify lead compounds for potential therapeutic applications in solid tumors.

Main Methods:

• Design of combi-molecules incorporating a quinazoline moiety (for EGFR) and a 7-phenyl-pyrazolopyrimidine moiety (for Src).
• Molecular modeling to determine optimal linker attachment points (quinazoline 6-position, pyrazolopyrimidine 9-position).
• Synthesis of SB162, SB166, and SB163; evaluation of their inhibitory activity against Src and EGFR.

Main Results:

• SB163, featuring the longest linker, demonstrated dose-dependent inhibition of both Src and EGFR.
• SB163 also exhibited inhibitory effects on Abl and Platelet-Derived Growth Factor Receptor (PDGFR).
• Other synthesized compounds (SB162, SB166) did not show dual inhibition.

Conclusions:

• SB163 represents a promising dual inhibitor of Src and EGFR, with potential activity against Abl and PDGFR.
• This combi-molecule approach offers a viable strategy for developing targeted cancer therapies against metastatic solid tumors.